In the probe trial, pioglitazone-treated APP mice performed better than untreated APP mice in the number of platform crossings, but this measure failed to reach significance ( Fig. 2 E).
1
—
—
In the probe trial, pioglitazone-treated APP mice performed better than untreated APP mice in the number of platform crossings, but this measure failed to reach significance ( Fig. 2 E).